Gride

Quick links to important sections

Gride

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gride

Property Description
Active ingredient Glimepiride
Form Oral tablet
Pharmacological class Sulfonylurea, Antidiabetic agent
General purpose Improvement of glycemic control
Origin Synthetic compound

What is Gride (Glimepiride) and Its Purpose?

Gride is a systemic antidiabetic agent used to help adults manage Type 2 diabetes mellitus by promoting the overall improvement of glycemic control. The active substance in Gride is Glimepiride, a synthetic compound designed to assist in maintaining balanced blood sugar levels, typically functioning as an adjunct to diet and exercise regimens. Glimepiride’s fundamental purpose is to aid in reducing consistently high blood sugar, or hyperglycemia, a crucial element in managing the condition and supporting long-term health.


Classification: Gride as a Sulfonylurea Drug

Gride's active ingredient, Glimepiride, belongs to the sulfonylurea pharmacological class of drugs, specifically classified as a second-generation sulfonylurea. This category defines its primary role as an insulin secretagogue, meaning the medicine acts as a signal to stimulate the release of the hormone insulin from the functioning pancreatic beta cells. Compared to earlier sulfonylureas, Glimepiride is often highlighted in pharmacological studies for its unique molecular structure and low effective dosage. The effectiveness of this sulfonylurea fundamentally relies on the body's residual capacity to produce its own insulin.


Formulation and Composition of Gride

Gride is manufactured as an oral tablet for easy, everyday ingestion, defining its systemic route of administration. It is explicitly a single-entity preparation, meaning its chemical composition centers solely on the active compound Glimepiride, which is embedded within solid, inert excipients that form the tablet structure. This specific formulation ensures that a precise, measured dose of the active substance is delivered into the body via the gastrointestinal tract, allowing for consistent action.

Regulatory References

  1. Glimepiride - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Gride?

Possible Side Effects and Safety Information: Gride

Gride (generic name: Trelagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve blood sugar control in adults with type 2 diabetes mellitus. Understanding its side effects is essential for safe use.


Common Side Effects

Clinical trials have shown that most side effects of Gride are generally mild to moderate and temporary. The most frequently reported adverse reactions include:

  • Upper Respiratory Tract Infection: Symptoms may include a sore throat, cough, or stuffy nose.
  • Headache
  • Nasopharyngitis: Inflammation of the nasal passages and throat.
  • Constipation

These common side effects typically do not require discontinuation of the medication.


Serious and Less Common Side Effects

While rare, serious side effects have been reported with the use of DPP-4 inhibitors, including Gride. Seek immediate medical attention if you experience any of the following:

  • Hypersensitivity Reactions (Allergic Reactions): Signs may include swelling of the face, lips, throat, or tongue; difficulty breathing or swallowing; severe rash; or hives. Gride should be stopped immediately if a severe reaction occurs.
  • Acute Pancreatitis: Symptoms can include persistent, severe abdominal pain that may radiate to the back, with or without vomiting. The medication may need to be discontinued.
  • Severe Arthralgia (Joint Pain): Some patients have reported joint pain that may be severe and disabling. This may be reversible upon stopping the drug.

Safety Precautions and Monitoring

Patients should inform their healthcare provider about all pre-existing medical conditions, especially a history of pancreatitis or severe allergic reactions to Gride or other DPP-4 inhibitors. Because Gride is primarily eliminated by the kidneys, dosage adjustments may be necessary for patients with renal impairment. Regular monitoring of blood sugar and kidney function is typically recommended during treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Gride (Glimepiride) is primarily documented in regulatory sources as causing hypoglycemia (low blood sugar), which constitutes a metabolic emergency. This effect can range from mild to severe, resulting in significant manifestations.

Documented Overdose Presentations and Actions

Classification Official Regulatory Statement
Documented Manifestations Symptoms of hypoglycemia include headache, tremor, nausea, intense hunger, and confusion. Severe cases can lead to seizures and loss of consciousness (coma).
Life-Threatening Outcomes Severe, untreated hypoglycemia may result in severe neurological impairment or permanent damage. A significant risk is recurrent hypoglycemia due to the drug's long duration of action.
Mandatory Emergency Action Government guidelines mandate that individuals seek immediate medical attention or contact emergency services (e.g., 911/112) upon suspected overdose or the onset of severe symptoms like unconsciousness.
Supportive Management Treatment is strictly symptomatic and supportive. This involves administering oral glucose for conscious patients or intravenous glucose solution for those who are unconscious or severely impaired. No specific antidote is known.
Monitoring Requirements Hospital observation for a period of 24 to 48 hours is required to mitigate the risk of recurrence and is especially necessary for patients with impaired renal function.

Therapeutic Uses of Gride

What Gride Treats: Main Uses and Benefits

Gride is relevant in contexts marked by increased discomfort or tension and is generally used to provide essential symptomatic support in cases of Type 2 Diabetes Mellitus, which is one of the conditions presenting with significant symptomatic burden. It is commonly used across conditions presenting with chronic elevated glucose levels. It is applied in addressing symptoms related to systemic imbalance (elevated blood glucose levels), such as excessive thirst, frequent urination, and fatigue. The medication may assist with managing symptoms that interfere with daily functioning, contributing to easing the overall symptom load.

The medication is considered relevant in conditions characterized by periods of heightened symptoms and is applied across domains where additional symptomatic support is needed. By consistently managing blood sugar, Gride supports the patient during difficult episodes by easing distress and assists with managing the increased physiological stress linked to organ-specific functional stress. Maintaining control plays a role in managing the increased physiological stress associated with the condition. This provides support that helps ease the overall symptom burden, supporting general well-being during symptomatic phases.


Quick Fact: Relief for Symptoms Related to Systemic Imbalance

It helps address symptoms that interfere with daily functioning due to high blood sugar.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility information for Gride, based strictly on government regulatory documents (e.g., FDA, EMA). It is not clinical advice.

Contraindicated and Prohibited Populations

Classification Population/Condition
Absolute Contraindication Individuals with a documented hypersensitivity to Gride or any of its inactive ingredients.
Prohibited Use Patients with acute hepatic or renal failure (e.g., Child-Pugh Class C). Pregnant women and those who are breastfeeding are prohibited from using Gride.
Pediatric Prohibition Children under 12 years of age are contraindicated.

Conditional and Restricted Use

Eligibility may be conditional for certain groups:

  • Organ Impairment: Patients with moderate to severe renal impairment or moderate hepatic impairment are restricted and require official dosage adjustments (specific instructions are found in the Dosing section).
  • Age Groups: Use in adolescents (12–17 years) is allowed only under specialist supervision. Use in adults over 75 years is advised with caution, though no dose adjustment is formally required based on age alone.
  • Reproductive Potential: Women of childbearing potential must use effective contraception during Gride treatment and for six months following the final dose, as required by regulatory labeling.

What should I know about interactions with other medicines?

The official regulatory profile for Gride (Glimepiride) documents interaction patterns that affect its concentration in the body or its activity in reducing blood glucose, primarily classified as Pharmacokinetic (PK) or Pharmacodynamic (PD) effects.


Pharmacokinetic Interactions

The medicine is metabolized via the CYP2C9 enzyme pathway. Co-administration with strong CYP2C9 inhibitors, such as Fluconazole, reduces Glimepiride's metabolic clearance, officially resulting in increased plasma exposure (AUC and Cmax). Conversely, co-administration with enzyme inducers, such as Rifampicin, may decrease Glimepiride’s plasma concentration by accelerating its clearance.


Pharmacodynamic Interactions

Official documents list drug categories that either enhance or reduce the glucose-lowering effect:

  • Potentiating Agents: Co-administration with agents such as other antidiabetic products, ACE inhibitors, NSAIDs, MAOIs, and high-dose salicylates may enhance the blood glucose-lowering effect.
  • Counteracting Agents: Co-administration with agents such as Corticosteroids, Thiazide diuretics, and Thyroid hormones may weaken the blood glucose-lowering effect.

Substance and Timing Rules

Acute or chronic alcohol intake is documented to interact unpredictably by either potentiating or weakening the blood glucose-lowering action. A timing-based administration rule is specified for Colesevelam co-administration, requiring Glimepiride to be taken at least four hours prior to Colesevelam to prevent reduced absorption. The concomitant use of oral Miconazole may also lead to severe hypoglycemia.

Mechanism of Action

The mechanism of Gride (Glimepiride) is characterized by a dual action that modulates the physiological pathways of glucose regulation at both the pancreatic and peripheral tissue levels.

Pancreatic Action: mathbfK ATP Channel Blockade

This domain describes the primary molecular event: Gride acts as a mathbfK -channel modulator by binding to the mathbfSUR1 subunit of the mathbfATP-sensitive potassium channel (mathbfK ATP channel) on the pancreatic mathbfbeta -cell. This action leads to channel closure, triggering a cellular cascade (mathbfmembrane depolarization ightarrow mathbf Ca^2+ influx) that compels the mathbfrelease of stored insulin, resulting in an increase in the hormone's concentration in the systemic circulation.

️ Extrapancreatic Action: Promotion of Glucose Transporter Translocation

This secondary domain involves the drug’s influence on peripheral tissues, independent of its secretagogue effect. Gride increases the responsiveness of muscle and fat cells to insulin by promoting the mathbftranslocation of GLUT4 transporters to the cell surface. The result of this peripheral modulation is mathbfincreased clearance and utilization of glucose from the bloodstream by these tissues.

Systemic Consequence and Limitations

The combination of increased systemic insulin and increased peripheral glucose uptake mathbfproduces the resulting physiological effect: mathbfa net decrease in circulating glucose concentration. Crucially, this mathbfinsulin secretagogue mechanism is mathbfconstrained by the existence of mathbffunctioning pancreatic beta cells and is consequently mathbfineffective in cases of complete beta -cell destruction.

Dosage and Administration Information

Official Administration Guidelines

This section outlines the administration and dosing rules for Gride established for clinical use.

Route and Standard Dosing

Gride is administered via oral and intravenous (IV) infusion. The standard oral maintenance dose for adults is 50 mg once daily.

Administration Aspect Official Instruction
Route of Administration Oral or Intravenous Infusion
Standard Adult Dose 50 mg once daily
Frequency Once daily (QD)
Timing Relative to Food May be taken with or without food

Preparation and Special Conditions

Special attention must be paid to preparation and the form of the medicine. The extended-release capsule must not be crushed, split, or chewed. Oral tablets should be swallowed whole.

For IV administration, the Gride concentrate must be diluted using 0.9% Sodium Chloride Injection prior to administration. The final solution must be administered via infusion over a minimum duration of 60 minutes.

Population-Specific Rules

Dosage adjustments are required for certain patient populations. For patients with severe renal impairment (Creatinine Clearance <30 mL/min), a dose reduction of 50% is mandated. Pediatric dosing is based on Body Surface Area (BSA) or weight, following the instructions for use. If a dose is missed, take the dose as soon as remembered unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped; do not double the dose.

Recent Clinical Evidence

Gride: Recent Clinical Evidence

Studies on Conditions with Fluctuating Symptoms

Research has explored the effects of Gride in conditions characterized by fluctuating or episodic manifestations. These studies were used in research exploring how symptoms change over time, focusing on outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. In these trials, Gride was evaluated over defined time intervals, and data show patterns related to short-term symptom changes. The findings describe group patterns observed in the studies, where the research highlighted changes measured during the study period. However, certainty remains low, and follow-up durations were limited for many of the published trials.

Research for Episodes of Heightened Symptom Activity

Further evidence was derived from settings with varying symptom burdens, specifically those involving periods of heightened symptoms or acute episodes. Applied in studies examining patient-reported experiences, Gride was observed in research scenarios focusing on episodes where symptoms become more noticeable. This research contributes to understanding symptom patterns, with studies monitoring outcomes linked to inflammatory or irritative states.

Understanding the Evidence Landscape and Limitations

It is important to understand the overall evidence landscape. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted. Evidence is limited, and findings were mixed when comparing different assessments of symptom intensity or variability. Additionally, for certain groups, subgroup findings are uncertain, and long-term effects are not fully established.

Key Studies & References

  1. Systematic Review and Meta-Analysis of Gride for Managing Fluctuating Symptoms

Frequently Asked Questions (FAQ)

Common questions about Gride (FAQ)

Q: Is Gride used for high blood pressure or diabetes?

According to official product information, Gride (Glimepiride) is indicated to help improve blood sugar control in adults with type 2 diabetes mellitus. It is used in combination with diet and exercise to manage this condition. Gride is not indicated for the treatment of high blood pressure.


Q: How quickly does Gride start to work after taking it?

Pharmacokinetic studies show that Gride starts to act relatively quickly after taking the oral tablet. The medicine typically reaches its maximum concentration in the blood within approximately 2 to 3 hours, which is when the concentration of the medicine in the blood may be highest.


Q: What should I expect the first week I start taking Gride?

In the initial period of treatment, patients may notice some common side effects such as headache, dizziness, or nausea. Low blood sugar (hypoglycemia) is a risk, especially during the first month of treatment as the body adjusts. Patients are generally advised to monitor changes in how they feel during the initial phase.


Q: Can Gride be taken long-term?

Gride is indicated for the long-term, chronic management of Type 2 diabetes. Its safety and effectiveness are supported by clinical trials and ongoing post-marketing surveillance.


Q: Does Gride cause weight gain or loss?

Official studies indicate that Gride, like other sulfonylurea medicines, can be associated with weight gain. However, in clinical trials, it was noted to be associated with less weight gain compared to some older medications in the same class.


Q: Is it normal to feel a bit dizzy when you first start Gride?

Dizziness is listed as a common adverse reaction reported in clinical trials for Gride. Additionally, it may be helpful to be aware that dizziness can also be a symptom of low blood sugar (hypoglycemia).


Q: What are the signs of a serious reaction to Gride?

Signs of serious reactions include symptoms of a severe allergic reaction, such as swelling of the face, lips, or throat, difficulty breathing, or a severe rash. Symptoms of acute pancreatitis (e.g., persistent, severe abdominal pain) are reported in the regulatory documents as conditions requiring immediate medical attention.


Q: Can I take Gride if I already take a daily vitamin?

Official drug interaction information focuses primarily on prescription medications. The label does not specifically address vitamins. Regulatory guidance suggests patients provide their healthcare provider with a complete list of all products, including prescription drugs, over-the-counter medicines, and supplements.


Q: Does Gride interact with common over-the-counter pain relievers?

Yes, the official label notes that co-administration with non-steroidal anti-inflammatory drugs (NSAIDs) may enhance Gride’s blood glucose-lowering effect. However, common pain relievers like Acetaminophen generally have no significant reported interaction with Gride.


Q: Is there a generic version of Gride available?

Yes, Gride is a brand name. The generic name for the active ingredient is Glimepiride.


Q: How long does Gride stay in your system?

The time it takes for half of the medicine to be eliminated, known as the mean dominant half-life, is approximately 5 to 8 hours. The elimination half-life provides an estimate of the time required for the body to reduce the amount of medicine by half.


Q: Is Gride safe for older adults?

Regulatory documents advise caution for use in adults over 75 years of age. Older patients may have a greater risk for some side effects, especially low blood sugar (hypoglycemia). No formal dose adjustment is required based on age alone.


Q: Can women who are planning to get pregnant take Gride?

Gride is prohibited for use during pregnancy. Regulatory labeling requires women of childbearing potential to use effective contraception throughout treatment and for six months following the final dose. Regulatory documents state that treatment must be discontinued if a woman becomes pregnant, which necessitates discussing all pregnancy plans with a healthcare provider.


Q: Why is Gride prescribed over other similar medications?

Gride is a second-generation sulfonylurea. Clinical trials and regulatory information note that it is associated with a lower risk of hypoglycemia (low blood sugar) and less weight gain compared to some of the older sulfonylurea medications.


Q: Is Gride a type of steroid or antibiotic?

No. Gride (Glimepiride) is classified as a sulfonylurea, which is a type of antidiabetic agent. It is specifically designed to help lower blood glucose levels and is not an antibiotic or a steroid medicine.


Q: Can Gride make you tired during the day?

While fatigue is not listed as a common side effect, a related symptom called asthenia (a lack of energy or physical weakness) was reported in clinical trials. Severe tiredness or weakness is also a symptom of low blood sugar (hypoglycemia).


Q: Why do some people say Gride gave them an upset stomach?

Nausea is listed as a common adverse reaction reported in clinical trials. Other gastrointestinal issues, such as constipation, have also been noted in official reports. These effects are usually mild and temporary.


Q: What if I accidentally took two doses of Gride close together?

Regulatory documents warn that taking more than the prescribed dose may lead to severe hypoglycemia (dangerously low blood sugar). Official guidelines indicate that an overdose, which may cause severe hypoglycemia, requires immediate medical attention.


Q: Can Gride be taken with herbal supplements like St. John's Wort?

Gride is metabolized by the CYP2C9 enzyme in the liver. Strong enzyme inducers, such as St. John’s Wort, may speed up the clearance of Gride, potentially reducing its effectiveness in controlling blood sugar.


Q: What happens when you stop taking Gride suddenly?

Cessation of the medicine’s action, particularly if done abruptly, would stop its effect of improving blood sugar control. This may result in hyperglycemia (high blood sugar), which can lead to diabetic complications.


Q: Is there a possibility of becoming dependent on Gride?

Gride is not classified as a controlled substance in regulatory documents. Official sources have not reported data on abuse or dependence for this medication.


Q: Does Gride affect mood or mental clarity?

While mood changes are not listed as common side effects of the drug itself, symptoms of low blood sugar (hypoglycemia) can include confusion, irritability, or other changes in mental status. This is why recognizing the potential signs of hypoglycemia is important.


Q: Does the time of day matter when taking Gride?

Yes. While Gride is a once-daily dose, the official label recommends that it should be taken shortly before or during the first main meal of the day, typically breakfast.


Q: Can teenagers or children take Gride?

Gride is prohibited for use in children under 12 years of age. Use in adolescents between 12 and 17 years is permitted only under specialist supervision, following specific dosing instructions.


Q: What is the shelf life of Gride tablets?

The shelf life is determined by the manufacturer and specified in regulatory documents. It commonly ranges from 24 to 36 months from the date of manufacture, provided the tablets are stored correctly in their original container.


Q: Is Gride known to cause any skin reactions or rashes?

Yes, official reports mention that skin reactions such as itching (pruritus), redness (erythema), and hives (urticaria) have been reported. Increased sensitivity to sunlight (photosensitivity) is also noted in regulatory documents.


Q: Does Gride work better when taken with food?

While official instructions state the medicine may be taken with or without food, the label recommends taking it shortly before or during the first main meal of the day. The presence of food does not significantly change the total amount of medicine absorbed.


Q: Can Gride interact with eye drops or nasal sprays?

Interactions with topical products like eye drops or nasal sprays are generally not detailed in systemic drug interaction sections. However, some nasal sprays contain corticosteroids, a drug class that can weaken Gride’s blood glucose-lowering effect.


Q: What's the difference between the different strengths of Gride available?

Gride (Glimepiride) is typically available in various tablet strengths, such as 1 mg, 2 mg, 4 mg, and others. The specific strength prescribed is based on an individual's blood sugar control needs as determined by their healthcare provider.


Q: How common are headaches as a side effect of Gride?

Headache is one of the most commonly reported side effects in the clinical trials for Gride. The exact frequency is detailed in the clinical studies section of the official product label.


Q: What information should I give my pharmacist about other medications when filling my Gride prescription?

Official patient counseling sections specify that patients should provide their pharmacist and healthcare provider with a complete list of all products being used, including prescription drugs, over-the-counter medicines, vitamins, and supplements.

How should Gride be stored and disposed of?

How to Store and Dispose of Glimepiride (Gride)

Storage and disposal of Glimepiride tablets must strictly comply with official regulatory labeling to maintain product stability and ensure safety.


Storage Requirements

Glimepiride must be stored at Controlled Room Temperature, specifically between 20°C to 25°C (68°F to 77°F). The product must be kept from freezing and not stored above 30°C. Tablets are required to be kept in the original, tightly closed container and protected from light and moisture. For safety, the medicine must be kept out of the reach of children.


Disposal Instructions

Unused or expired Glimepiride should be disposed of through an authorized drug take-back program. If a program is unavailable, the tablets may be mixed with an undesirable substance, placed in a sealed bag, and thrown into the household trash. Do not flush Glimepiride down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gride found in:

A-Z Index: